Androgen receptor signaling blockade enhances NK cell-mediated killing of prostate cancer cells and sensitivity to NK cell checkpoint blockade

Androgen receptor inhibitors enhance natural killer (NK) cell-mediated killing of prostate cancer cells but also upregulate the inhibitory ligand HLA-E, a mechanism that can be overcome to further boost therapeutic efficacy by combining AR inhibitors with NKG2A checkpoint blockade.

The Gist

The Big Picture: A Two-Pronged Attack on Prostate Cancer

Imagine prostate cancer cells as sneaky burglars hiding in a house (the body). For a long time, doctors have tried to stop these burglars by cutting off their power supply (using Androgen Receptor inhibitors, or "ARi"). This works well at first, but eventually, the burglars adapt, hide better, and keep stealing (the cancer returns).

This paper discovers a new strategy: Don't just cut the power; wake up the security guards.

The researchers found that when you cut the power to the burglars (using drugs like Enzalutamide or Darolutamide), it actually wakes up the body's natural "security guards" (called NK cells). However, the burglars have a clever trick: they put up a "Do Not Disturb" sign to keep the guards away. The researchers found that if you combine the power-cutting drugs with a special tool that removes the "Do Not Disturb" sign, the security guards become incredibly effective at catching the burglars.

---

The Key Players

1. The Burglars (Prostate Cancer Cells): They rely on a signal called "Androgen" (male hormones) to grow and survive.
2. The Power Cutters (AR Inhibitors): These are standard drugs (like Enzalutamide) that stop the hormones from talking to the cancer cells.
3. The Security Guards (NK Cells): These are Natural Killer cells, part of the immune system. They are like the neighborhood patrol that can spot and destroy bad cells.
4. The "Do Not Disturb" Sign (HLA-E): This is a protein on the surface of cancer cells. It acts like a shield. When the security guard sees this sign, it thinks, "Oh, this is a friendly house," and stops attacking.
5. The Sign Remover (Monalizumab): This is a new type of drug (an antibody) that blocks the "Do Not Disturb" sign, forcing the security guards to do their job.

---

What the Researchers Discovered

1. Turning the Power Cut into a Wake-Up Call

Usually, we think of cutting the power to cancer cells as just starving them. But the researchers found something surprising: When you use the power-cutting drugs, the cancer cells actually scream for help.

• The Analogy: Imagine the burglars are so stressed by the power outage that they start shouting. This shouting (releasing chemicals like IFN-γ and TRAIL) wakes up the sleeping security guards (NK cells).
• The Result: The guards become more alert, carry more weapons (Granzyme B and Perforin), and start hunting the cancer cells more aggressively.

2. The Burglars' Counter-Attack

Here is the tricky part. While the power-cutting drugs wake up the guards, the cancer cells try to defend themselves.

• The Analogy: As the guards get closer, the burglars quickly tape up a big "POLICE DO NOT ENTER" sign (HLA-E) on their front door.
• The Mechanism: The study found that the stress of the power-cutting drugs actually makes the cancer cells put more of these "Do Not Disturb" signs on their surface. This tricks the guards into backing off, allowing the cancer to survive.

3. The Winning Combination

The researchers realized that to win, you need to do both things at once:

1. Cut the power (use the standard drug) to wake up the guards.
2. Remove the sign (use the new drug, Monalizumab) so the guards aren't tricked.

• The Result: When they combined these two strategies in the lab and in mice, the security guards didn't just wake up; they went into "super mode." They destroyed the cancer cells much faster and more effectively than with either method alone.

---

Real-World Proof

The researchers didn't just test this in a petri dish.

• In Mice: They created a scenario where the "Do Not Disturb" sign was physically removed (genetically deleted). When they gave these mice the power-cutting drug, the tumors shrank much faster than in mice that still had the sign.
• In Humans: They looked at blood samples from prostate cancer patients before and after they started hormone therapy. They found that after treatment, the patients' natural killer cells were indeed "woken up" and carrying more weapons, proving the theory works in real people.

Why This Matters

Prostate cancer is often "cold," meaning the immune system ignores it. This study suggests a new playbook:

• Old Way: Just try to starve the cancer.
• New Way: Starve the cancer and simultaneously remove its camouflage so the body's own immune system can finish the job.

This opens the door for combining existing, common prostate cancer drugs with new immunotherapy drugs (like Monalizumab) to treat patients who have stopped responding to standard care. It's like upgrading the security system of the house to ensure the burglars never get a second chance.

Technical Summary

1. Problem Statement

Prostate cancer (PCa) is the second leading cause of cancer-related death in men. While Androgen Receptor (AR) signaling blockade is the standard of care, most patients eventually progress to metastatic castration-resistant prostate cancer (mCRPC). Immunotherapies, particularly immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1, have shown limited efficacy in mCRPC due to the "cold" tumor microenvironment (TME), characterized by low T-cell infiltration and immunosuppressive mechanisms.

While it is known that AR signaling suppresses CD8+ T-cell function, the impact of AR blockade on Natural Killer (NK) cells—a critical component of innate immunity—remains poorly understood. Furthermore, the interplay between AR signaling, NK cell activation, and the expression of inhibitory ligands (such as HLA-E) on tumor cells is unknown. This study aims to elucidate how AR inhibitors (ARi) affect NK cell cytotoxicity and whether combining ARi with NK cell checkpoint blockade (specifically targeting NKG2A) can overcome resistance in PCa.

2. Methodology

The study employed a multi-faceted approach combining in vitro co-culture assays, molecular biology, in vivo mouse models, and clinical sample analysis.

• Cell Lines: Human PCa lines (LNCaP, 22Rv1, PC3, DU145) and the NK-92 cell line. Murine RM-1 cells were used for in vivo studies.
• Interventions:
  • AR Inhibitors: Enzalutamide (Enza) and Darolutamide (Daro).
  • Checkpoint Blockade: Monalizumab (anti-NKG2A antibody).
  • Blocking Antibodies: Anti-IFN-γ and Anti-TRAIL (RIK-2) to determine mechanistic pathways.
  • Genetic Manipulation:
    • CRISPR-Cas9 was used to knock out the murine HLA-E ortholog (H2-T23) in RM-1 cells.
    • Lentiviral transduction was used to stably express AR in AR-negative cell lines (PC3, DU145) to test AR-dependency.
• Assays:
  • Co-culture Killing: PCa cells and NK cells were co-cultured (1:1 ratio) with fluorescent dyes (CMAC/CMFDA/EthD-1) to quantify tumor cell death via high-content imaging.
  • Cytokine Profiling: Luminex assays measured cytokine secretion (IFN-γ, TRAIL, IL-10, etc.) from NK cells and PCa cells.
  • Flow Cytometry: Analyzed surface expression of NKG2A on NK cells, HLA-E on PCa cells, and activation markers (CD69, CD137, Granzyme B, Perforin).
  • In Vivo Model: C57BL/6 mice were castrated and implanted with H2-T23 (HLA-E) wild-type or knockout RM-1 tumors, treated with Darolutamide.
  • Clinical Samples: Peripheral blood NK cells from mCRPC patients were analyzed pre- and post-Androgen Deprivation Therapy (ADT).

3. Key Contributions

• Novel Mechanism of ARi: Demonstrated that AR inhibitors directly activate NK cells, increasing their cytotoxicity against PCa cells via IFN-γ and TRAIL secretion.
• Dual Role of ARi on HLA-E: Revealed a paradoxical effect where ARi upregulates the expression of HLA-E (the ligand for the inhibitory receptor NKG2A) on AR-dependent tumor cells. This suggests ARi may inadvertently induce an immune escape mechanism by suppressing NK cells via the NKG2A/HLA-E axis.
• Therapeutic Synergy: Identified that combining ARi with Monalizumab (anti-NKG2A) overcomes the HLA-E-mediated suppression, significantly enhancing NK cell-mediated tumor killing.
• Epigenetic Regulation: Provided evidence that the regulation of HLA-E by androgen signaling involves epigenetic mechanisms (HDACs), as HDAC inhibitors could block androgen-mediated HLA-E repression.

4. Key Results

• Enhanced NK Killing: ARi (Enza/Daro) significantly increased NK-92 mediated killing of PCa cell lines (LNCaP, PC3, DU145, 22Rv1), regardless of the cell line's intrinsic sensitivity to ARi.
• Mechanism of Activation:
  • ARi treatment increased secretion of cytotoxic cytokines IFN-γ and TRAIL from NK cells.
  • Blocking IFN-γ or TRAIL reversed the enhanced killing effect; dual blockade abolished it almost entirely.
  • ARi increased expression of NK activation markers (CD69, CD137).
• HLA-E Upregulation:
  • ARi treatment increased surface HLA-E expression on AR-sensitive cells (LNCaP) but not on AR-resistant lines (22Rv1) or AR-negative lines (PC3, DU145) unless AR was ectopically expressed.
  • This upregulation creates a negative feedback loop, potentially limiting the efficacy of ARi alone.
• Synergy with Monalizumab:
  • Monalizumab alone had no effect on killing.
  • However, combining Monalizumab with ARi (Enza/Daro) significantly potentiated NK cell killing, particularly in AR-sensitive lines, by blocking the NKG2A-HLA-E inhibitory signal.
• In Vivo Validation:
  • In a mouse model, H2-T23 (HLA-E) knockout tumors showed reduced growth.
  • Darolutamide treatment further inhibited tumor growth in H2-T23 KO mice compared to wild-type, confirming that removing the HLA-E checkpoint enhances ARi efficacy.
  • Darolutamide increased NK cell infiltration (NK1.1) and Granzyme B expression, particularly in the absence of HLA-E.
• Clinical Correlation:
  • Patient-derived NK cells collected after ADT initiation showed significantly increased expression of Granzyme B and Perforin compared to pre-treatment levels, confirming the in vitro findings in a clinical setting.

5. Significance and Conclusion

This study redefines the immunomodulatory role of Androgen Receptor Inhibitors in prostate cancer. It establishes that while ARi activates NK cells to kill tumor cells, it simultaneously upregulates the inhibitory ligand HLA-E, which dampens this response.

Clinical Implications:

• New Combination Strategy: The data strongly supports a novel therapeutic strategy combining AR inhibitors (Enza/Daro) with NKG2A blockade (Monalizumab). This combination leverages the activation of NK cells by ARi while simultaneously blocking the tumor's escape mechanism (HLA-E upregulation).
• Overcoming "Cold" Tumors: This approach offers a pathway to convert the immunologically "cold" prostate cancer microenvironment into a "hot" one by engaging the innate immune system (NK cells), potentially benefiting patients who do not respond to T-cell-centric therapies (PD-1/PD-L1 inhibitors).
• Biomarker Potential: HLA-E expression levels and NK cell activation status (Granzyme B/Perforin) could serve as biomarkers for patient stratification in future clinical trials.

The authors conclude that targeting the AR-NKG2A-HLA-E axis represents a promising, clinically translatable platform for treating advanced prostate cancer.